文献速递慢性静脉疾病

利伐沙班用于静脉腔内激光消融联合或不联合静脉切除术后的血栓预防

Rivaroxaban for thrombosis prophylaxis in endovenous laser ablation with and without phlebectomy.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2017-02-21

本研究为多中心回顾性单臂观察性研究,纳入2012至2014年间接受大隐、副大隐或小隐静脉EVLA并采用10 mg/d利伐沙班预防EHIT的患者。中位随访51天,438次手术中完全静脉闭塞率98.4%,仅1例EHIT 2级(0.2%),无大出血,6例轻微出血(1.4%)。结论认为利伐沙班10 mg/d用5至10天似乎是EVLA联合或不联合静脉切除术后预防EHIT的有效且安全的选择。

要点

  • 利伐沙班10 mg/d用5至10天预防EHIT,EHIT 2级发生率0.2%。
  • 无大出血事件,轻微出血发生率1.4%。
  • 完全静脉闭塞率达98.4%,疗效满意。

核心结论

  • 利伐沙班10 mg/d用5至10天似乎是EVLA联合或不联合静脉切除术后预防EHIT的有效且安全的选择。

研究设计与样本

  • 研究者发起的多中心回顾性观察性单臂研究,纳入2012至2014年间接受EVLA并采用10 mg/d利伐沙班预防EHIT的患者。
  • 共纳入306例患者、438次EVLA手术,中位随访51天(四分位距41-68天)。

主要发现

  • 438次EVLA手术中完全静脉闭塞率达98.4%。
  • 1例患者发生EHIT 2级(0.2%;95%CI 0.006%-1.3%)。
  • 无大出血事件(0%;95%CI 0.0%-0.8%),6例轻微出血(1.4%;95%CI 0.5%-3%)。

关键数值与推荐

  • EHIT分级采用Kabnick分类,疗效终点为EHIT等级≥2。
  • 利伐沙班剂量为10 mg/d,疗程5至10天。

临床怎么用

  • 对于接受EVLA联合或不联合静脉切除术的患者,可考虑使用利伐沙班10 mg/d用5至10天预防EHIT。

局限性

  • 本研究为回顾性单臂观察性研究,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovenous heat-induced thrombosis (EHIT) is a well-described complication of endovenous laser ablation (EVLA). We report our centers' experience on the efficacy (EHIT level ≥2 according to the Kabnick classification) and safety (observed major and minor bleeding events) of rivaroxaban for EHIT prophylaxis in EVLA with and without concomitant phlebectomy. METHODS: Demographic, procedural, and outcome data of all patients with EVLA of the great, accessory, or small saphenous vein and EHIT prophylaxis with 10 mg/d rivaroxaban between 2012 and 2014 were reviewed and analyzed in this investigator-initiated multicenter retrospective observational single-arm study. RESULTS: During a median (interquartile range) follow-up duration of 51 (41-68) days, complete vein occlusion was achieved in 98.4% of 438 EVLA procedures in 306 patients. One patient had an EHIT level 2 (0.2%; 95% confidence interval, 0.006%-1.3%). No major bleedings (0%; 95% confidence interval, 0.0%-0.8%) and six minor bleedings (1.4%; 95% confidence interval, 0.5%-3%) were observed. CONCLUSIONS: Rivaroxaban (10 mg/d) for 5 to 10 days seems to be an efficacious and safe alternative for EHIT prophylaxis in EVLA with or without phlebectomy.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Uthoff H, Holtz D, Broz P, et al. Rivaroxaban for thrombosis prophylaxis in endovenous laser ablation with and without phlebectomy. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 28623988. doi:10.1016/j.jvsv.2016.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。